Should an otherwise stable 80-year-old keep taking a cholesterol pill that may have been started decades earlier?
A new clinical trial suggests the answer may be more complicated than simply assuming that statins should always continue for life.
In a study of adults aged 75 and older who had never suffered a heart attack or stroke, stopping statin treatment did not increase deaths during three years of follow-up. The result is notable because strong evidence about preventive statin use in very old adults has been limited.
Statins work mainly by reducing LDL cholesterol. LDL particles can carry cholesterol into artery walls, where it contributes to plaque that may eventually narrow or block blood vessels.
Lowering LDL is a major part of preventing atherosclerotic cardiovascular disease. Statins have therefore become a standard treatment for people with established heart disease and for many people considered likely to develop it.
But prevention changes with age. A medicine that offers a clear benefit over several decades to a 50-year-old may have a different balance of benefits and burdens for someone who is 80, particularly when that person has several other health conditions or takes many medications.
Older adults have also been left out of many statin trials. Most of the evidence supporting statins for primary prevention comes from populations substantially younger than 75, making it difficult to know exactly how much benefit very old adults receive.
Researchers in France designed a randomized trial to investigate this question directly. They recruited 1,160 people aged at least 75 from general practices, all of whom were taking statins but had no previous history of heart disease or stroke.
Participants were assigned by chance to one of two approaches. One group discontinued statins, while the other continued taking them as usual.
Three years later, the researchers compared deaths between the groups. Among participants with available outcome data, 7.2% of those assigned to stop statins had died, compared with 7.9% of those assigned to continue.
That difference was not considered statistically significant. Major cardiovascular events, including heart attacks and strokes, were also not significantly different between the two groups during the trial.
At first glance, this could suggest that the statins were doing little. But the cholesterol results tell a more complicated story.
Within three months of stopping treatment, average LDL cholesterol increased by about half, rising from 115 mg/dL to 171 mg/dL. People who remained on statins did not experience a similar increase.
In other words, statins continued to do exactly what they are designed to do: keep LDL cholesterol lower. What remained uncertain was whether that lower cholesterol translated into a measurable survival or cardiovascular advantage within the study’s three-year time frame.
The researchers also looked at how participants felt and functioned. Physical and mental quality-of-life scores remained similar whether people stopped or continued the medication.
This is useful information for discussions about treatment burden in older age. Some people may value reducing the number of daily medicines they take, while others may prefer to continue a familiar treatment even when the size of the long-term benefit is uncertain.
But the trial cannot answer what happens after three years. Damage from high LDL accumulates over time, and benefits from statin therapy may also become more apparent after longer periods.
The findings also do not apply to everyone who takes statins. People with previous heart attacks, strokes or other established cardiovascular disease generally have a stronger reason for cholesterol-lowering treatment, and this trial specifically excluded them.
Nor should an older person stop a statin simply because of their age. Individual risk depends on many factors, including cholesterol, blood pressure, diabetes, smoking history, kidney health, general fitness, other illnesses and personal goals for treatment.
The research was published in The Lancet Healthy Longevity. It adds rare randomized evidence to a question that has been difficult to answer because adults over 70 or 80 have often been excluded or poorly represented in cardiovascular prevention trials.
The study has a valuable strength: participants were randomly assigned to stop or continue treatment, reducing many of the differences that can distort observational research. Its biggest uncertainty is time, because three years is short compared with the decades over which cholesterol can affect artery health.
The most useful conclusion is therefore not that statins become unnecessary at 75. Rather, the study supports individualized decision-making, in which older adults and their clinicians weigh uncertain long-term preventive benefits against medication burden, side effects, overall health and what matters most to the patient.
If you care about heart health, please read studies that yogurt may help lower the death risks in heart disease, and coconut sugar could help reduce artery stiffness.
For more information about health, please see recent studies that Vitamin D deficiency can increase heart disease risk, and results showing vitamin B6 linked to lower death risk in heart disease.
Source: French primary care research team.
